Neurofibromatosis Therapeutic Acceleration Program
About Neurofibromatosis Therapeutic Acceleration Program
Neurofibromatosis Therapeutic Acceleration Program is dedicated to advancing treatment options for individuals with plexiform neurofibromas and cutaneous neurofibromas. In order to do this, it identifies the most promising opportunities to develop effective therapies, delivers support to develop these ideas, and removes obstacles to ensure patients benefit from research advances. NTAP uses a collaborative approach that brings together patients, clinicians, researchers, industry, and government to determine where resources are most effectively deployed to produce treatments.
Missing: Neurofibromatosis Therapeutic Acceleration Program's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Neurofibromatosis Therapeutic Acceleration Program's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Neurofibromatosis Therapeutic Acceleration Program Frequently Asked Questions (FAQ)
Where is Neurofibromatosis Therapeutic Acceleration Program's headquarters?
Neurofibromatosis Therapeutic Acceleration Program's headquarters is located at 600 North Wolfe Street, Baltimore.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.